| Post |
| Pre |
| LA |
|---|
| - |
| - |
| ME 1 | ME 2 | ME 3 | ME 4 | ME 5 | ME 6 | ME 7 | ME 8 | ME 9 | ME 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 | - | 3 | - | - | 3 | - | - | - | - | 13 |
| 2 | 4 | - | - | - | - | - | - | - | - | 6 |
| Post |
| Pre |
| LO 1 | LO 2 | LO 3 | LO 4 | LO 5A | LO 5B | LO 6 | Total |
|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - |
| AME |
|---|
| 79 |
| 45 |
| Post |
| Pre |
| LOP 1 | LOP 2 | LOP 3 | LOP 4 | Total |
|---|---|---|---|---|
| - | - | - | - | - |
| - | - | - | - | - |
| central brain |
|---|
| 55 |
| 45 |

| ROI Name | ∑ In | % In | log ratio | ∑ Out | % Out |
|---|---|---|---|---|---|
| Optic-unspecified(L) | 179 | 54.9% | -1.60 | 59 | 38.1% |
| AME(L) | 79 | 24.2% | -0.81 | 45 | 29.0% |
| CentralBrain-unspecified | 55 | 16.9% | -0.29 | 45 | 29.0% |
| ME(L) | 13 | 4.0% | -1.12 | 6 | 3.9% |
| upstream partner | # | NT | conns aMe_unclear | % In | CV |
|---|---|---|---|---|---|
| aMe4 (L) | 9 | ACh | 53 | 16.9% | 0.5 |
| MeVP1 (L) | 21 | ACh | 39 | 12.4% | 0.7 |
| aMe12 (L) | 4 | ACh | 36 | 11.5% | 0.4 |
| HBeyelet (L) | 4 | HA | 33 | 10.5% | 0.3 |
| MeVPaMe2 (R) | 1 | Glu | 32 | 10.2% | 0.0 |
| aMe6b (L) | 1 | ACh | 17 | 5.4% | 0.0 |
| MeVP5 (L) | 7 | ACh | 16 | 5.1% | 0.5 |
| MeVPMe11 (R) | 1 | Glu | 11 | 3.5% | 0.0 |
| aMe1 (L) | 2 | GABA | 10 | 3.2% | 0.6 |
| aMe12 (R) | 2 | ACh | 10 | 3.2% | 0.2 |
| OA-AL2i3 (L) | 2 | OA | 8 | 2.5% | 0.2 |
| MeVC10 (R) | 1 | ACh | 7 | 2.2% | 0.0 |
| MeVPMe4 (R) | 1 | Glu | 7 | 2.2% | 0.0 |
| MeVPMe3 (R) | 1 | Glu | 5 | 1.6% | 0.0 |
| Cm33 (L) | 1 | GABA | 5 | 1.6% | 0.0 |
| L3 (L) | 1 | ACh | 4 | 1.3% | 0.0 |
| aMe17a (L) | 1 | unc | 3 | 1.0% | 0.0 |
| aMe6c (L) | 2 | Glu | 3 | 1.0% | 0.3 |
| l-LNv (R) | 1 | unc | 2 | 0.6% | 0.0 |
| MeVPMe12 (L) | 1 | ACh | 2 | 0.6% | 0.0 |
| aMe5 (L) | 2 | ACh | 2 | 0.6% | 0.0 |
| aMe6a (L) | 1 | ACh | 1 | 0.3% | 0.0 |
| aMe23 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| aMe2 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| Cm20 (L) | 1 | GABA | 1 | 0.3% | 0.0 |
| aMe30 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| LoVP96 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| l-LNv (L) | 1 | unc | 1 | 0.3% | 0.0 |
| Cm30 (L) | 1 | GABA | 1 | 0.3% | 0.0 |
| Cm35 (L) | 1 | GABA | 1 | 0.3% | 0.0 |
| downstream partner | # | NT | conns aMe_unclear | % Out | CV |
|---|---|---|---|---|---|
| aMe4 (L) | 10 | ACh | 100 | 30.1% | 0.5 |
| MeVPMe12 (L) | 2 | ACh | 44 | 13.3% | 0.0 |
| MeVPaMe2 (L) | 1 | Glu | 36 | 10.8% | 0.0 |
| aMe10 (L) | 1 | ACh | 29 | 8.7% | 0.0 |
| aMe5 (L) | 7 | ACh | 17 | 5.1% | 0.4 |
| MeVP49 (L) | 1 | Glu | 15 | 4.5% | 0.0 |
| aMe15 (L) | 1 | ACh | 11 | 3.3% | 0.0 |
| aMe12 (L) | 4 | ACh | 9 | 2.7% | 0.5 |
| Cm35 (L) | 1 | GABA | 8 | 2.4% | 0.0 |
| MeVP5 (L) | 5 | ACh | 8 | 2.4% | 0.5 |
| aMe1 (L) | 1 | GABA | 6 | 1.8% | 0.0 |
| l-LNv (L) | 2 | unc | 5 | 1.5% | 0.2 |
| aMe6c (L) | 2 | Glu | 5 | 1.5% | 0.2 |
| aMe24 (L) | 1 | Glu | 4 | 1.2% | 0.0 |
| DNp27 (L) | 1 | ACh | 2 | 0.6% | 0.0 |
| aMe23 (L) | 1 | Glu | 2 | 0.6% | 0.0 |
| aMe6b (L) | 1 | ACh | 2 | 0.6% | 0.0 |
| MeVP3 (L) | 1 | ACh | 2 | 0.6% | 0.0 |
| MeVPMe9 (L) | 1 | Glu | 2 | 0.6% | 0.0 |
| Pm12 (L) | 1 | GABA | 2 | 0.6% | 0.0 |
| MeVP30 (L) | 1 | ACh | 2 | 0.6% | 0.0 |
| Cm33 (L) | 1 | GABA | 2 | 0.6% | 0.0 |
| MeVCMe1 (R) | 1 | ACh | 2 | 0.6% | 0.0 |
| MeLo7 (L) | 2 | ACh | 2 | 0.6% | 0.0 |
| aMe12 (R) | 2 | ACh | 2 | 0.6% | 0.0 |
| aMe26 (L) | 1 | ACh | 1 | 0.3% | 0.0 |
| Dm9 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| Lat3 (L) | 1 | unc | 1 | 0.3% | 0.0 |
| MeVP1 (L) | 1 | ACh | 1 | 0.3% | 0.0 |
| Cm24 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| aMe30 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| MeVC10 (R) | 1 | ACh | 1 | 0.3% | 0.0 |
| SLP250 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| MeVPaMe2 (R) | 1 | Glu | 1 | 0.3% | 0.0 |
| MeVC21 (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| MeVP29 (L) | 1 | ACh | 1 | 0.3% | 0.0 |
| aMe17c (L) | 1 | Glu | 1 | 0.3% | 0.0 |
| OA-AL2i3 (L) | 1 | OA | 1 | 0.3% | 0.0 |